EDP Sciences logo
Submit your paper
Search
Menu
Home All issues Volume 18 / No 1 (février 2012) Med Buccale Chir Buccale, 18 1 (2012) 9-15 References
Open Access
Issue
Med Buccale Chir Buccale
Volume 18, Number 1, février 2012
Page(s) 9 - 15
Section Articles originaux / Original articles
DOI https://doi.org/10.1051/mbcb/2011144
Published online 02 December 2011
  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws : a growing epidemic. J Oral Maxillofac Surg 2003;61 :115-7. [CrossRef] [Google Scholar]
  2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates : a review of 63 cases. J Oral Maxillofac Surg 2004;62 :527-34. [CrossRef] [PubMed] [Google Scholar]
  3. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9 :2893-7. [PubMed] [Google Scholar]
  4. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007;74 :32-8. [CrossRef] [PubMed] [Google Scholar]
  5. Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease : beyond their antiresorptive activity. Cancer Res 2005;65 :4971-4. [CrossRef] [PubMed] [Google Scholar]
  6. Jimenez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis : an update. Med Oral Patol Oral Cir Bucal 2005;10(Suppl 2) :E88-91. [PubMed] [Google Scholar]
  7. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182 :417-8. [PubMed] [Google Scholar]
  8. Bauss F, Dempster DW. Effects of ibandronate on bone quality : preclinical studies. Bone 2007;40 :265-73. [CrossRef] [PubMed] [Google Scholar]
  9. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone : therapeutic implications. Bone 1997;21 :373-7. [CrossRef] [PubMed] [Google Scholar]
  10. Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention, and treatment. Quintessence Publishing Co Inc. Chicago, 2007. [Google Scholar]
  11. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C. Avascular jaw osteonecrosis in association with cancer chemotherapy : series of 10 cases. J Oral Pathol Med 2005;34 :120-3. [CrossRef] [PubMed] [Google Scholar]
  12. Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D’Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P. Bone necrosis of the jaws associated with bisphosphonate treatment : a report of twenty-nine cases. Acta Biomed 2006;77 :109-17. [PubMed] [Google Scholar]
  13. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis : a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7 :508-14. [CrossRef] [PubMed] [Google Scholar]
  14. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D. Osteonecrosis of the jaw : more research needed. J Bone Miner Res 2006;21 :1503-5. [CrossRef] [PubMed] [Google Scholar]
  15. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates : incidence and risk factors. J Clin Oncol 2005;23 :8580-7. [CrossRef] [PubMed] [Google Scholar]
  16. Kim T, Hong J, Park E, Kim S. Vascular endothelial growth factor gene polymorphism is associated with increased risk of femoral head osteonecrosis. J Bone Miner Res 2006;21(Suppl 1) :243. [Google Scholar]
  17. Woeller A, Gering A, Brix M, Bettega G, Lebeau J. Ostéonécrose des maxillaires sous bisphosphonates : cinq cas. Rev Stomatol Chir Maxillofac 2006;107 :417-22. [CrossRef] [PubMed] [Google Scholar]
  18. Boivin G, Meunier PJ. Histomorphometric methods applied to bone (pp. 137-56). In Histology of ancient human bone. Grupe G, Garland AN Ed., Springer, Berlin, 1993. [Google Scholar]
  19. Boivin G, Meunier PJ. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 2002;70 :503-11. [CrossRef] [PubMed] [Google Scholar]
  20. Boivin G, Meunier PJ. Methodological considerations in measurement of bone mineral content. Osteoporos Int 2003;14 (Suppl 5) :22-8. [CrossRef] [Google Scholar]
  21. Boivin G, Bala Y, Doublier A, Farlay D, Ste-Marie LG, Meunier PJ, Delmas PD. The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone 2008;43 :532-8. [CrossRef] [PubMed] [Google Scholar]
  22. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws : risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63 :1567-75. [CrossRef] [PubMed] [Google Scholar]
  23. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302 :1055-61. [CrossRef] [PubMed] [Google Scholar]
  24. Kaczmarczyk-Sedlak I, Janiec W. Effects of catecholamines on blood pressure in the long bone marrow cavity in rats with bisphosphonate-induced osteopetrosis. Pharmacol Rep 2005;57 :623-34. [PubMed] [Google Scholar]
  25. Germanier Y, Carrel JP, Abi Najm S, Samson J. Ostéopétrose ou maladie des os de marbre - 3. Manifestations stomatologiques. Med Buccale Chir Buccale 2007;13 :37-48. [Google Scholar]
  26. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;7 :687-94. [CrossRef] [Google Scholar]
  27. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients : clinical features and risk factors. J Clin Oncol 2006;24 :945-52. [CrossRef] [PubMed] [Google Scholar]
  28. Sanna G, Zampino MG, Pelosi G, Nolè F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncol 2005;16 :1207-8. [CrossRef] [PubMed] [Google Scholar]
  29. Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MG, Paula LM, Paula AP, Guerra EN. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102 :14-21. [CrossRef] [PubMed] [Google Scholar]
  30. Burr DB. Targeted and nontargeted remodeling. Bone 2002;30 :2-4. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.